At the heart of every oncology breakthrough is trustworthy data. Researchers rely on access to complete, accurate, timely, longitudinal information about cancer patients to observe the impacts of new therapies in clinical trials and make decisions about what to recommend for individuals with cancer in the community.
But getting access to enough high-quality real-world data (RWD) hasn’t always been easy for life science companies and their research partners. It can be time-consuming, challenging, and expensive to develop datasets on one’s own, especially without established experience in the space.
That’s why COTA has partnered with Aetion®, a global leader in real-world evidence (RWE) and analytics, to make it faster and easier to access fit-for-purpose datasets for research. By combining the power of the Aetion Evidence Platform® (AEP) with COTA’s clinically curated, multi-source oncology Vantage RWD assets, investigators will be able to streamline access to meaningful data so they can focus on the science instead.
This collaboration enables Aetion and COTA to meet the needs of researchers requiring high-quality, clinically rich oncology data, for both liquid and solid tumor types. COTA’s newly expanded Vantage datasets in multiple myeloma (MM), non-small cell lung cancer (NSCLC), and acute myeloid leukemia (AML) are now available for use on AEP, in addition to other cancer-specific datasets from COTA.
COTA is already an active member of the Aetion CARE Initiative, a cross-industry, cross-functional initiative to better understand the role of RWD and RWE in emulating trials for evaluating oncology therapeutics.
The CARE team is working on designing emulated clinical trials using RWD and RWE with less restrictive inclusion/exclusion criteria than standard randomized controlled trials. The goal is to balance scientific rigor with inclusiveness and representation when developing cancer drugs that must be safe and effective for a wide variety of patients in real-world clinical settings.
Their findings will inform the next generation of cancer research and provide further proof points that RWD and RWE have a critical role to play in the future of clinical trials.